Related references
Note: Only part of the references are listed.Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition
Ketan S. Gajiwala et al.
STRUCTURE (2013)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Global Kinetic Explorer: A new computer program for dynamic simulation and fitting of kinetic data
Kenneth A. Johnson et al.
ANALYTICAL BIOCHEMISTRY (2009)
Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values
Ben-Fillippo Krippendorff et al.
JOURNAL OF BIOMOLECULAR SCREENING (2009)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Discovering potent and selective reversible inhibitors of enzymes in complex proteomes
D Leung et al.
NATURE BIOTECHNOLOGY (2003)
Tyrosine kinase inhibitors.: 17.: Irreversible inhibitors of the epidermal growth factor receptor:: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
JB Smaill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
